Evidence map›Paper›PMID 39143326›Full record

ReviewBritish journal of cancer2024

Deregulation of mitochondrial gene expression in cancer: mechanisms and therapeutic opportunities.

Mariah J Berner, Steven W Wall, Gloria V Echeverria

Abstract readReview
In one paragraph

Review in British journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Mitochondrial Ribosomal Proteins and Cancer.Medicina (Kaunas, Lithuania) · 2025
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mariah J BernerLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Steven W WallLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Gloria V EcheverriaLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA. gloria.echeverria@bcm.edu.ORCID http://orcid.org/0000-0002-3772-9298

Funding

Metabolic adaptation in residual triple negative breast cancer following chemotherapyR37CA269783 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Gloria Vittone Echeverria · 2023 to 2026
$2.1M
Translational Breast Cancer Research Training ProgramT32CA203690 · NCI · BAYLOR COLLEGE OF MEDICINE · PI FUQUA, SUZANNE AW, RIMAWI, MOTHAFFAR FAHED · 2018 to 2022
$1.0M
American Cancer Society (American Cancer Society, Inc.) RSG-22-093-01-CCBCancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) RR200009National Science Foundation (NSF) 2140736NCI NIH HHS R37 CA269783NCI NIH HHS T32 CA203690U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R37CA269783-01A1U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) T32CA203690
6 · The paper itself

Abstract

"Reprogramming of energy metabolism" was first considered an emerging hallmark of cancer in 2011 by Hanahan & Weinberg and is now considered a core hallmark of cancer. Mitochondria are the hubs of metabolism, crucial for energetic functions and cellular homeostasis. The mitochondrion's bacterial origin and preservation of their own genome, which encodes proteins and RNAs essential to their function, make them unique organelles. Successful generation of mitochondrial gene products requires coordinated functioning of the mitochondrial 'central dogma,' encompassing all steps necessary for mtDNA to yield mitochondrial proteins. Each of these processes has several levels of regulation, including mtDNA accessibility and protection through mtDNA packaging and epigenetic modifications, mtDNA copy number through mitochondrial replication, mitochondrial transcription through mitochondrial transcription factors, and mitochondrial translation through mitoribosome formation. Deregulation of these mitochondrial processes in the context of cancers has only recently been appreciated, with most studies being correlative in nature. Nonetheless, numerous significant associations of the mitochondrial central dogma with pro-tumor phenotypes have been documented. Several studies have even provided mechanistic insights and further demonstrated successful pharmacologic targeting strategies. Based on the emergent importance of mitochondria for cancer biology and therapeutics, it is becoming increasingly important that we gain an understanding of the underpinning mechanisms so they can be successfully therapeutically targeted. It is expected that this mechanistic understanding will result in mitochondria-targeting approaches that balance anticancer potency with normal cell toxicity. This review will focus on current evidence for the dysregulation of mitochondrial gene expression in cancers, as well as therapeutic opportunities on the horizon.

Indexed as

DNA, MitochondrialGene Expression Regulation, NeoplasticMitochondriaNeoplasmsAnimalsEpigenesis, GeneticGenes, MitochondrialHumansMitochondrial ProteinsDNA, MitochondrialMitochondrial Proteins

Identifiers

PMID39143326
PMCPMC11519338

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.